問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of Thoracic Medicine

Division of Radiology

Division of General Internal Medicine

Division of Hematology & Oncology

Taipei Chang Gung Medical Foundation

Division of Hematology & Oncology

更新時間：2023-09-19

王智亮Wang, Chih-Liang
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

Recruiting Trial

83Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王智亮

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

List

36Cases

2025-04-01 - 2033-01-20

Not yet recruiting
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Frozen Crystal Injection

Participate Sites
9Sites

Recruiting9Sites

2019-04-01 - 2025-12-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting8Sites

Terminated2Sites

2020-10-26 - 2024-10-01

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting6Sites

Terminated3Sites

2020-09-15 - 2025-10-08

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2023-01-30 - 2025-10-06

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting8Sites

2009-10-15 - 2011-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2008-05-01 - 2011-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-09-01 - 2013-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2022-08-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2018-10-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB